This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or Lymphomas

This study has been completed.
Information provided by (Responsible Party):
National Cancer Institute (NCI) Identifier:
First received: January 7, 2005
Last updated: June 4, 2013
Last verified: June 2013
This phase I trial is studying the side effects and best dose of oxaliplatin when given together with irinotecan in treating young patients with refractory solid tumors or lymphomas. Drugs used in chemotherapy, such as oxaliplatin and irinotecan, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Oxaliplatin may help irinotecan kill more cancer cells by making cancer cells more sensitive to the drug. Giving oxaliplatin together with irinotecan may kill more cancer cells.

Condition Intervention Phase
Childhood Burkitt Lymphoma Childhood Central Nervous System Germ Cell Tumor Childhood Diffuse Large Cell Lymphoma Childhood Grade III Lymphomatoid Granulomatosis Childhood Immunoblastic Large Cell Lymphoma Recurrent Childhood Brain Stem Glioma Recurrent Childhood Cerebellar Astrocytoma Recurrent Childhood Cerebral Astrocytoma Recurrent Childhood Ependymoma Recurrent Childhood Grade III Lymphomatoid Granulomatosis Recurrent Childhood Large Cell Lymphoma Recurrent Childhood Liver Cancer Recurrent Childhood Lymphoblastic Lymphoma Recurrent Childhood Malignant Germ Cell Tumor Recurrent Childhood Medulloblastoma Recurrent Childhood Rhabdomyosarcoma Recurrent Childhood Small Noncleaved Cell Lymphoma Recurrent Childhood Soft Tissue Sarcoma Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor Recurrent Childhood Visual Pathway Glioma Recurrent Colon Cancer Recurrent Ewing Sarcoma/Peripheral Primitive Neuroectodermal Tumor Recurrent Melanoma Recurrent Nasopharyngeal Cancer Recurrent Neuroblastoma Recurrent Osteosarcoma Recurrent Wilms Tumor and Other Childhood Kidney Tumors Recurrent/Refractory Childhood Hodgkin Lymphoma Unspecified Childhood Solid Tumor, Protocol Specific Drug: irinotecan hydrochloride Drug: oxaliplatin Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase I Study of Oxaliplatin (NSC# 266046, IND #57004) and Irinotecan in Pediatric Patients With Refractory Solid Tumors and Lymphomas

Resource links provided by NLM:

Further study details as provided by National Cancer Institute (NCI):

Primary Outcome Measures:
  • MTD of oxaliplatin, defined as the maximum dose at which fewer than one-third of patients experience DLT [ Time Frame: 21 days ]
    Graded using the NCI CTCAE version 3.0.

Secondary Outcome Measures:
  • Overall response assessed using RECIST criteria [ Time Frame: Up to 12 months ]

Enrollment: 24
Study Start Date: March 2005
Primary Completion Date: September 2007 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Treatment (irinotecan hydrochloride, oxaliplatin)
Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.
Drug: irinotecan hydrochloride
Given IV
Other Names:
  • Campto
  • Camptosar
  • CPT-11
  • irinotecan
  • U-101440E
Drug: oxaliplatin
Given IV
Other Names:
  • 1-OHP
  • Dacotin
  • Dacplat
  • Eloxatin
  • L-OHP

Detailed Description:


I. Determine the maximum tolerated dose of oxaliplatin when administered with irinotecan in pediatric patients with refractory solid tumors or lymphomas.

II. Determine the toxic effects of this regimen in these patients. III. Determine the pharmacokinetics of this regimen in these patients.


I. Determine, preliminarily, the antitumor activity of this regimen in these patients.

II. Correlate UGT and BCRP genotype with the toxicity of this regimen in these patients.

OUTLINE: This is a multicenter, dose-escalation study of oxaliplatin.

Patients receive oxaliplatin IV over 2 hours on days 1 and 8 and irinotecan IV over 1 hour on days 1-5 and 8-12. Treatment repeats every 21 days for up to 17 courses in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of oxaliplatin until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity.


Ages Eligible for Study:   1 Year to 21 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Histologically confirmed refractory malignant solid tumor or lymphoma

    • Intrinsic brain stem tumors and optic pathway tumors do not require histologic verification
  • No known curative therapy or therapy proven to prolong survival with an acceptable quality of life exists
  • Measurable or evaluable disease

    • Evaluable disease is defined as a tumor that cannot be measured using a ruler or calipers, but can be assessed to determine disease progression or complete response, such as any of the following:

      • Positive lesions on metaiodobenzylguanidine (MIBG) or bone scan
      • Metastatic bone marrow disease
      • Elevated tumor markers
      • Presence of a malignant pleural effusion
  • No leukemia
  • Performance status - Karnofsky 50-100% (for patients > 10 years of age)
  • Performance status - Lansky 50-100% (for patients ≤ 10 years of age)
  • Not specified
  • Absolute neutrophil count ≥ 1,000/mm^3
  • Platelet count ≥ 100,000/mm^3 (transfusion independent)
  • Hemoglobin ≥ 8.0 g/dL (transfusion allowed)
  • Bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • ALT ≤ 5 times ULN
  • Albumin ≥ 2 g/dL
  • Creatinine clearance or radioisotope glomerular filtration rate ≥ 70 mL/min
  • Creatinine based on age as follows:

    • No greater than 0.8 mg/dL (for patients age 5 and under)
    • No greater than 1.0 mg/dL (for patients age 6 to 10)
    • No greater than 1.2 mg/dL (for patients age 11 to 15)
    • No greater than 1.5 mg/dL (for patients age 16 and over)
  • No arrhythmia on EKG
  • No evidence of dyspnea at rest
  • No exercise intolerance
  • Pulse oximetry > 94% on room air and no evidence of pulmonary fibrosis by chest radiograph* or CT scan
  • Not pregnant
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Weight ≥ 10 kg
  • Neurologic deficits relatively stable for ≥ 1 week before study entry (patients with CNS tumors only)
  • No electrolyte (e.g., sodium, potassium, bicarbonate, calcium, magnesium, and phosphate) abnormality ≥ grade 2 (electrolyte supplementation allowed)
  • No uncontrolled infection
  • No history of life-threatening allergy to camptothecin derivatives or platinum agents
  • No sensory or motor peripheral neuropathy ≥ grade 2
  • No elevation of amylase or lipase ≥ grade 2
  • Able to tolerate enteral medications (e.g., cefixime, cefpodoxime, or loperamide)
  • Recovered from all prior immunotherapy
  • At least 7 days since prior hematopoietic growth factors
  • At least 7 days since prior antineoplastic biologic therapy
  • Prior stem cell transplantation or rescue without total-body irradiation (TBI) allowed provided ≥ 3 months have elapsed and there is no evidence of active graft-versus-host disease
  • No concurrent immunotherapy
  • No concurrent biologic therapy
  • More than 3 weeks since prior myelosuppressive chemotherapy (6 weeks for nitrosoureas) and recovered
  • No prior oxaliplatin
  • No other concurrent chemotherapy
  • Concurrent steroids allowed provided dose has been stable for ≥ 7 days before study entry
  • See Biologic therapy
  • Recovered from all prior radiotherapy
  • At least 2 weeks since prior local palliative small port radiotherapy
  • At least 6 months since prior TBI
  • At least 6 months since prior craniospinal, whole spinal, or whole lung/abdominal radiotherapy
  • At least 6 months since prior radiotherapy to ≥ 50 % of the pelvis
  • At least 6 weeks since other prior substantial radiotherapy to the bone marrow
  • No concurrent radiotherapy
  • No other concurrent investigational drugs
  • No other concurrent anticancer therapy
  • No concurrent cephalosporin antibiotics
  • No concurrent use of any of the following:

    • Phenytoin
    • Carbamazepine
    • Oxcarbazepine
    • Barbiturates
    • Rifampin
    • Phenobarbital
    • Azole antifungal agents
    • Aprepitant
    • Hypericum perforatum (St. John's wort)
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00101270

United States, California
COG Phase I Consortium
Arcadia, California, United States, 91006-3776
Sponsors and Collaborators
National Cancer Institute (NCI)
Principal Investigator: Lisa McGregor COG Phase I Consortium
  More Information

Responsible Party: National Cancer Institute (NCI) Identifier: NCT00101270     History of Changes
Other Study ID Numbers: NCI-2012-01819
U01CA097452 ( U.S. NIH Grant/Contract )
Study First Received: January 7, 2005
Last Updated: June 4, 2013

Additional relevant MeSH terms:
Lymphoma, Non-Hodgkin
Hodgkin Disease
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Lymphoma, Large B-Cell, Diffuse
Burkitt Lymphoma
Lymphoma, Large-Cell, Immunoblastic
Plasmablastic Lymphoma
Liver Neoplasms
Neoplasms, Germ Cell and Embryonal
Sarcoma, Ewing
Neuroectodermal Tumors
Neuroectodermal Tumors, Primitive
Wilms Tumor
Lymphomatoid Granulomatosis
Rhabdomyosarcoma, Embryonal
Lymphoma, Extranodal NK-T-Cell
Nasopharyngeal Neoplasms
Neuroectodermal Tumors, Primitive, Peripheral
Kidney Neoplasms
Optic Nerve Glioma processed this record on September 21, 2017